[go: up one dir, main page]

DK3538542T3 - Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin - Google Patents

Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin Download PDF

Info

Publication number
DK3538542T3
DK3538542T3 DK17870529.9T DK17870529T DK3538542T3 DK 3538542 T3 DK3538542 T3 DK 3538542T3 DK 17870529 T DK17870529 T DK 17870529T DK 3538542 T3 DK3538542 T3 DK 3538542T3
Authority
DK
Denmark
Prior art keywords
peptime
multimizes
4beta
alfa
integrin
Prior art date
Application number
DK17870529.9T
Other languages
English (en)
Inventor
Monzur M Morshed
Sai Kumar Chakka
Jennifer L Hickey
Manuel Perez Vazquez
Andrew Roughton
Adam Paul Kafal
Narendrakumar B Patel
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Application granted granted Critical
Publication of DK3538542T3 publication Critical patent/DK3538542T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK17870529.9T 2016-11-11 2017-11-10 Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin DK3538542T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421117P 2016-11-11 2016-11-11
PCT/CA2017/000244 WO2018085921A1 (en) 2016-11-11 2017-11-10 CYCLIC PEPTIDES MULTIMERS TARGETING α4β7 INTEGRIN

Publications (1)

Publication Number Publication Date
DK3538542T3 true DK3538542T3 (da) 2021-10-11

Family

ID=62110102

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17870529.9T DK3538542T3 (da) 2016-11-11 2017-11-10 Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin

Country Status (8)

Country Link
US (3) US11111273B2 (da)
EP (2) EP3538542B1 (da)
JP (2) JP7035044B2 (da)
CN (1) CN110088121A (da)
CA (1) CA3042576A1 (da)
DK (1) DK3538542T3 (da)
ES (1) ES2884107T3 (da)
WO (1) WO2018085921A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085921A1 (en) 2016-11-11 2018-05-17 Encycle Therapeutics, Inc. CYCLIC PEPTIDES MULTIMERS TARGETING α4β7 INTEGRIN
MX2019013362A (es) 2017-05-10 2020-08-17 Zealand Pharma As PÉPTIDOS CÍCLICOS HOMODÉTICOS CON LA INTEGRINA A4ß7 COMO DIANA.
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230117920A1 (en) * 2019-12-27 2023-04-20 The University Of Tokyo Library Construction Method, Cyclic Peptide, FXIIa Binder and IFNGR1 Binder
US20230295235A1 (en) * 2020-06-29 2023-09-21 Zealand Pharma A/S Compounds targeting alpha4-beta7 integrin
IL313590A (en) 2021-12-20 2024-08-01 Zealand Pharma As Compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3219113A1 (de) 1982-05-21 1983-11-24 Bayer Ag, 5090 Leverkusen Verwendung von n-substituierten 2,3-diaminocarbonsaeuren in arzneimitteln und ihre herstellung
AU638264B2 (en) 1989-08-10 1993-06-24 Aventis Inc. Cyclic neurokinin a antagonists
US5296604A (en) 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
US5705481A (en) 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
AU681119B2 (en) 1993-05-17 1997-08-21 Fujisawa Pharmaceutical Co., Ltd. New polypeptide compound and a process for preparation thereof
US5693325A (en) 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
DE4415310A1 (de) 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
AU2958195A (en) 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US5696084A (en) 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
US6667407B2 (en) 2002-05-03 2003-12-23 Bayer Polymers Llc Process of making polyaziridines
DE602005025750D1 (de) 2004-04-15 2011-02-17 Proteolix Inc Verbindungen zur proteasomenzymhemmung
WO2008046232A1 (en) 2006-10-20 2008-04-24 Yudin Andrei K Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation
EP1961759A1 (en) 2007-02-21 2008-08-27 Universita'degli Studi Di Milano Integrin targeted cyclopeptide ligands, their preparation and use
WO2009141687A1 (en) 2008-05-22 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) New optically pure compounds for improved therapeutic efficiency
ES2634431T3 (es) * 2009-03-16 2017-09-27 The Governing Council Of The University Of Toronto Moléculas de aminoácidos cíclicos y procedimientos de preparación de las mismas
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
EP2556060A1 (en) 2010-04-08 2013-02-13 Ah Usa 42 Llc Substituted 3,5- diphenyl-isoxazoline derivatives as insecticides and acaricides
JP5952840B2 (ja) 2011-02-22 2016-07-13 レオ ファーマ アクティーゼルスカブ ケラチノサイトへの結合のための環状ペプチドおよびその結合体
ES2605939T3 (es) * 2012-01-27 2017-03-17 F. Hoffmann-La Roche Ag Conjugados de antagonistas de la integrina para una administración dirigida a células que expresan alfa-V-beta-3
WO2013161904A1 (ja) * 2012-04-24 2013-10-31 味の素株式会社 スルホンアミド誘導体及びその医薬用途
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
CN113621027A (zh) 2014-05-16 2021-11-09 领导医疗有限公司 α4β7整联蛋白硫醚肽拮抗剂
WO2016054445A1 (en) * 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US9809623B2 (en) 2014-10-01 2017-11-07 Protagonist Therapeutics, Inc. α4β7 peptide monomer and dimer antagonists
CA3004641A1 (en) 2015-11-11 2017-05-18 Encycle Therapeutics, Inc. Cyclic peptides targeting .alpha.4.beta.7 integrin
WO2018085921A1 (en) 2016-11-11 2018-05-17 Encycle Therapeutics, Inc. CYCLIC PEPTIDES MULTIMERS TARGETING α4β7 INTEGRIN

Also Published As

Publication number Publication date
EP3538542A4 (en) 2020-08-26
JP7429726B2 (ja) 2024-02-08
US12077611B2 (en) 2024-09-03
US11713338B2 (en) 2023-08-01
EP3538542A1 (en) 2019-09-18
US20230406884A1 (en) 2023-12-21
US11111273B2 (en) 2021-09-07
WO2018085921A1 (en) 2018-05-17
ES2884107T3 (es) 2021-12-10
JP7035044B2 (ja) 2022-03-14
CN110088121A (zh) 2019-08-02
US20200216501A1 (en) 2020-07-09
CA3042576A1 (en) 2018-05-17
EP3538542B1 (en) 2021-08-04
JP2022078188A (ja) 2022-05-24
US20210324007A1 (en) 2021-10-21
EP3939989A1 (en) 2022-01-19
JP2020504080A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
DK3519420T3 (da) Cykliske dinukleotidforbindelser
EP3454634A4 (en) SEED FILLING CLOSURE SENSORS
DK3405050T3 (da) Børnesikret snusbeholder
EP3503130A4 (en) R-T-B SINTERED MAGNET
EP3596108A4 (en) TARGETED IMMUNOTOLERANCE
EP3431075A4 (en) GALENIC FORM OF EDARAVONE
EP3466394A4 (en) ASSISTANCE DEVICE FOR MARKET MOVEMENT
EP3440949A4 (en) FLAVOR INHALER
EP3720871A4 (en) TARGETED IMMUNOTOLERANCE
DK3436823T3 (da) Antigen-array
EP3482772A4 (en) Antitumor agent
DK3335532T3 (da) Tandharve
EP3483213A4 (en) COMPOSITION OF ACRYLIC RUBBER
DK3445708T3 (da) Stigbøjle
DK3402792T3 (da) Quinolin-2-on-derivater
EP3402022A4 (en) GRAB WIRE
DK3538542T3 (da) Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
EP3466246A4 (en) HARVEST MANAGEMENT SYSTEM
DK3575238T3 (da) Pallecontainer
EP3402421A4 (en) UTERINE MANIPULATOR FORMING DEVICE
EP3468396A4 (en) CHICHA MELASS CAPSULES
EP3477092A4 (en) END CAP
EP3455282A4 (en) POLYSILOXANE-BASED HYDRAULIC FLUIDS
EP3494124A4 (en) CROSS COOPERATIVE SELF-ASSEMBLY